Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

A majority of patients noticed improvement in hyperpigmentation spots, skin texture and evenness after 12 weeks of use.

Novel Acne Scar Gel Has High Rates of Efficacy and Patient Satisfaction

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

EltaMD’s Derm Difference campaign honors dermatologists’ expertise in skin health, cancer prevention, and confidence-boosting care.

Celebrating Second Annual National Dermatologist Day with Launch of EltaMD’s ‘Derm Difference’ Campaign

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and is now finishing her Masters in Digital Media through Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family.

By leveraging the innovative biomarker panels, clinicians can now offer more personalized and effective treatment options for psoriasis and AD.

New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis

, MD, is founder of Dr. Seth L. Matarasso, San Francisco, California.

The COVID-19 pandemic reshaped dermatology through telehealth, social media, and increased cosmetic procedures. Challenges and opportunities persist as practices adapt.

Reshaping Dermatology: The Enduring Impact of COVID-19

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.  

Advancing Medical Treatments for Vitiligo With Amit Pandya, MD, FAAD 

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

The lip augmentation market is projected to reach a value of 11.6 billion USD by 2030.

 Although hyaluronic acid fillers are the most common type of lip procedure, an alternative method, the “lip flip,” has grown in popularity in recent years, with the #lipflip hashtag gaining 64.4 million views on TikTok as of July 2021.

 A lip flip involves injecting botulinum neurotoxin A (BoNT-A) into the superior orbicularis oris muscle, forming a more natural “pout” in the upper mouth. The technique is less expensive than a traditional dermal lip filler, but the effects have a more temporary duration of 8 to 12 weeks. Both methods have similar adverse effects of swelling and bruising at the injection site, but lip flips do not require much aftercare post-procedure.

“’Lip flips’ are ideal for patients who desire fuller lips but do not want lip fillers, have excessive gingival display while smiling, have an upper lip that retracts with their smile, or prefer relatively short-term or temporary results,” according to the study authors.

A novel longitudinal analysis evaluated shifts in public interest over the past decade regarding these minimally invasive lip augmentation strategies.

 Investigators used the Google Trends database to evaluate the historical monthly search volumes of “lip filler” and “lip flip” from January 2014 to January 2024.

Both search terms had similar increases in engagement across the 10-year period. However, lip filler was searched more consistently with an average 75% increase in relative search volume per month. Conversely, lip flip had a mean increase of 33%. Furthermore, the relative search volumes were quantified as 12.1 for lip flip and 30.4 for lip filler, giving “lip flip” a consistently lower Google search volume over time (

Even with these differences, both terms saw similar patterns across the years. For example, both saw a rapid decline at the onset of the COVID-19 pandemic,  between February 2020 and April 2020. Conversely, between September 2022 and February 2023, there was a stark increase in both categories' searches.

Even as lip flips grow in public interest, it still remains secondary to lip filler, according to this data. The research is limited, however, as the sole use of Google Trends does not provide information on patient factors like demographics, satisfaction, and outcomes. Including clinical surveys and data in future research could bolster these results and provide a more nuanced perspective on these procedures.

“This reveals a need for future research surrounding patient and physician education on minimally invasive lip augmentation procedures and what deciding factors are considered, such as safety, cost, or convenience,” the authors concluded. “It also emphasizes the need for future research assessing sociodemographic factors that play a role in cosmetic lip augmentation, ultimately allowing us to understand better the populations seeking these procedures and their accessibility.

Do you prefer lip filler or lip flips? Let us know your thoughts and experiences by answering our poll above and commenting on social media, or by writing to us at 

1. Grandview Research, “Lip Augmentation Market Size to Reach $11.61Bn By 2030,” (2023), 

https://www.grandviewresearch.com/press-release/global-lip-augmentation-market.

2. D. Shira, “Considering a Lip Flip? Here's Why Experts Say Proceed With Caution,” (2024), 

www.forbes.com/sites/dahvishira/2024/02/21/considering-a-lip-flip-heres-why-experts-say-proceed-with-caution/

3. Bourmand R, Olsson SE, Soleimani S, Fijany A. Lip Filler Versus "Lip Flip": Longitudinal Public Interest and a Brief Review of Literature. 

. 2025;24(2):e70048. doi:10.1111/jocd.70048

The lip augmentation market is expected to reach $11.6 billion by 2030, with hyaluronic acid fillers being the most common procedure. However, the "lip flip," which uses botulinum neurotoxin A, is gaining popularity due to its natural appearance and lower cost, despite its temporary effects. A longitudinal analysis using Google Trends showed that while both "lip filler" and "lip flip" searches increased over the past decade, lip fillers consistently had higher search volumes. The study highlights the need for further research on patient demographics and satisfaction to better understand these procedures.

Share your thoughts by answering today’s poll and read about these popular aesthetic techniques for lips.

Polls 

POLL: “Lip Flips” or Lip Filler? Analyzing the Latest Trends in Lip Augmentation 

It is time to consider non-pulse dye lasers in pediatric populations, Deepti Gupta, MD, shared at the Society for Pediatric Dermatology 37th Annual Pre-AAD Annual Meeting in Orlando, Florida.

 Gupta, a pediatric dermatologist at Seattle Children's Hospital and the University of Washington School of Medicine, provided a comprehensive overview of the role of lasers in pediatric dermatology. Her presentation focused on the use of laser hair removal for various medical conditions in pediatric patients, emphasizing both the therapeutic benefits and practical considerations of laser treatments in this population.

Although many pediatric dermatologists are familiar with pulse dye lasers, the use of non-pulse dye lasers, such as Alexandrite and diode lasers, remains less widespread, Gupta explained. She underscored the potential of these lasers as valuable tools for treating conditions such as congenital birthmarks, pigmented lesions, scarring, and hair removal in pediatric patients with underlying medical conditions.

Laser's role in broadening the pediatric toolbox

One of the key takeaways from Gupta’s session was the importance of tailoring laser treatments to the unique needs of pediatric patients. Unlike adults, children require additional considerations regarding pain management, tolerability, and treatment logistics. She emphasized the need for a multidisciplinary approach, involving the right support team to ensure safe and effective treatments.

Gupta also addressed concerns regarding the potential side effects of laser treatments in pediatric patients, including risks of dyspigmentation, blistering, and scarring. She posed critical questions regarding the long-term efficacy of early laser interventions, such as whether treatment in childhood increases the likelihood of recurrence or provides lasting results.

A crucial aspect of laser therapy, she noted, is engaging in shared decision-making with families. Educating patients and caregivers about the number of sessions required, expected discomfort, and potential outcomes helps set realistic expectations. She compared laser treatments to alternative modalities, such as surgical excision, highlighting how lasers may reduce surgical morbidity and improve long-term cosmetic outcomes. By sharing the pros and cons with families, clinicians can empower them to make the best treatment decision for the child.

Reflecting on the broader landscape of pediatric dermatology, Gupta expressed enthusiasm about the increasing availability of US Food and Drug Administration-approved treatments for chronic pediatric dermatologic conditions. She is eager to see how expanding therapeutic options, including both lasers and systemic treatments, will shape the future of pediatric dermatology.

Beyond the clinical insights, Gupta emphasized the value of the AAD Annual Meeting as a forum for knowledge exchange and collaboration. Like many others, she appreciates the opportunity to engage with fellow dermatologists, learn about emerging advancements, and collectively enhance patient care.

Gupta said she hoped her session would help clinicians better understand the evolving role of lasers in pediatric dermatology, and she encouraged dermatologists not to shy away from integrating these tools into their practice, ultimately expanding treatment options and improving patient outcomes.

2025 American Academy of Dermatology Annual Meeting

1. Gupta D. "Beyond PDL: Lasers for the Pediatric Dermatologist." Presented at: Society for Pediatric Dermatology 37th Annual Pre-AAD Annual Meeting; March 6, 2025; Orlando, Florida.  

Deepti Gupta, MD, highlighted the potential of non-pulse dye lasers, such as Alexandrite and diode lasers, in pediatric dermatology, particularly for conditions like congenital birthmarks and pigmented lesions. She emphasized the importance of tailoring treatments to pediatric needs, considering pain management and treatment logistics. Gupta also discussed the necessity of shared decision-making with families, addressing potential side effects and comparing laser treatments to surgical alternatives. She expressed optimism about the expanding therapeutic options in pediatric dermatology and encouraged clinicians to integrate lasers into their practice for improved patient outcomes.

Deepti Gupta, MD, discussed the importance of lasers at the Society for Pediatric Dermatology 37th Annual Pre-AAD Annual Meeting.

Lasers' Role in Broadening the Pediatric Toolbox 

“I want to set the stage for us in understanding what [hidradenitis suppurativa] HS is and what it isn't,” Colleen Cotton, MD, told attendees of the Society for Pediatric Dermatology's 37th Annual Pre-AAD (American Academy of Dermatology) Meeting in Orlando, Florida.

 Although it is still evolving, she explained it is considered “an inflammatory skin disease, a condition of the hair follicle is not a disease of sweat glands. It is not an infection, it is not a result of poor hygiene; these are things that many of your patients may have heard or seen on the internet.”

“It is multifactorial,” added Cotton, assistant professor of dermatology and assistant professor of pediatrics at George Washington School of Medicine and Health Sciences. “There are factors of follicular occlusion, hormones, obesity and insulin resistance, bacterial imbalance, the way that your immune system functions in general. And the importance of each of those different factors can be wildly different from one patient to another, which kind of impacts which treatments we ultimately decide to use. And then also recognizing that this is a chronic condition and progressive that may have periods of flares, but it's always kind of going—this is not something that acutely starts and stops.”

Cotton used 3 cases to help illustrate what HS is, what it is, and how to treat it. The first case was a girl aged12 years who presented with a history of boils under her armpit, with a family history of similar issues. The patient reported no evidence of drainage or pain in between episodes.

In mild cases, like this way, Cotton likes to start simple and, to some degree, follow the patient’s lead. She suggested the use of maintenance antimicrobial wash (eg, chlorhexidine gluconate 4% [Hibiclens]; benzoyl peroxide wash [5-10%], zinc pyrithione [eg, Head and Shoulders]). She also suggested a topic regimen to start, and suggested considering antibiotics (eg, clindamycin 1%, which comes as gel, lotion, wipes, solution) and resorcinol (phenol derivative with keratolytic properties; compounded). Oral antibiotics (eg, doxycycline) could be considered for 2 to 4 weeks for more severe flares, she added.

Her plan of attack is highly dependent on the patient and their needs, and she asks about where they struggle and what they are willing to try. She also works with them on their triggers to the right treatment strategy.

The second case she presented demonstrated the importance of an early diagnosis to strike during the best window of opportunity to impact the disease. The patient was a girl aged 15 years who presented with recurrent boils 2 to 3 times per year for the last 2 years. With a BMI in the 99 percentile, she has been told she is pre-diabetic and is trying to manage her weight via diet.

Again, Cotton emphasized comorbidities play an important role in determining the treatment strategy, and she highlighted the importance of team approach. She works closely with a psychologist and an adolescent medicine specialist to help hone the treatment approaches. She also has clinicians in other areas that she can reach out to, as needed.

Cotton told attendees she takes patients on what she likes to call a “medication march.” She starts with treatments that fast-acting to get buy-in from her patients and shows them they can trust her. Then she moves to the agents that might take time to work. “The medication march can minimize side effects and improve adherence,” she told attendees.

For instance, she would start week 1 with clindamycin in the morning and evening, to be taken with food. In week 2, she would add rifampicin, morning and evening with food. Twice daily metformin would be added to the regimen in week 3, and trace elements (eg, zinc and copper) in week 4.

Intralesional triamcinolone might also be useful. She aims for 20-40 mg/mL and dilutes with lidocaine. Cotton finds ice packs to be especially helpful for pain, but also offers distraction, numbing cream, and vibration.

The next case was more severe, with the patient, aged 13, always having at least 1 active lesion, and often seeing scars left behind. She reported that she is not doing well in school.

“We have adalimumab because of model-informed drug development,” Cotton told attendees, adding that there have been no phase 3 trials for HS that included adolescents. To complicate matters, many insurance companies will require scarring before approving adalimubab. Cotton likes to use the HS-PGA, which she can use a moderate score of 3, with 0 abscesses, 0 draining fistulas, and at least 5 inflammatory nodules, to help get the treatment covered. 

There are also off-label medications for HS that have either been approved for other indications in children, including secukinumab and infliximab, that may be considered, she said.

For persistent/recurring abscesses or draining tunnel when lesions are not resolving with medications, Cotton finds deroofing can be highly effective. She described the process, and included some important considerations for clinicians considering this for their patients. For instance, she emphasized the importance of medical treatment (ie, antibiotics and biologics) before and after the procedure to reduce active inflammation at the surgical site at the time of deroofing as well as to facilitate healing and reduce recurrence risk. Similarly, there are times when it is ok for clinicians to consider performing the deroofing themselves (ie, when the area is smaller and appears uncomplicated). Especially for clinicians newer to the procedure, she recommended referring to more experienced clinicians when the area is large, complex, or requires general anesthesia. She also stressed the importance of teaching and supporting proper wound care following the procedure, and recommended connecting with a wound care team.

Importantly, Cotton said patients are generally happy with the results following deroofing, and quoted data from a study that found 76% of patients were “very satisfied” with their surgical results.

Lastly, there may be times when inpatient care is warranted, Cotton said. She told the story of a patient with severe HS who presented with suicidal ideation. The young patient received a psych consult, who admitted to suicidal thoughts when the outbreaks were hardest for her. She received treatment and left the hospital 3 to 4 days letter feeling better physically and mentally.

Cotton shared additional thoughts to consider when treating patients. For instance, in pediatric populations, she is seeing more syndromic HS. In those cases, she likes biologics on fast track. Cotton also noted there has been an increase in immune dysregulation masquerading as HS. “If a patient is not responding or is getting worse on biologics, test for immune issues,” she cautioned attendees.

Although there has been some excitement over the possibility of leveraging GLP-1 for HS, Cotton is more cautious. She told attendees she was initially excited, but has found “it is magical for some, but nothing for others.” If the HS is related to insulin issues, Cotton said it might respond better.

For more conference coverage and expert insights, 

1. Cotton C. Advanced hidradenitis suppurativa for the pediatric dermatologist. Presented at: the 37th Annual SDP Pre-AAD Meeting; March 6, 2025; Orlando, Florida.

2. Ravi S, Miles JA, Steele C, Christiansen MK, Sayed CJ. Patient Impressions and Outcomes After Clinic-Based Hidradenitis Suppurativa Surgery. 

Colleen Cotton, MD, shared clinical tips in treating HS in pediatric patients at the annual SPD Pre-AAD Meeting. 

Pediatric Pearls in Treating HS Discussed at SPD Meeting 

L’Oréal announced today it is recalling all lots of its acne treatment

 in the US due to concerns over benzene contamination.

 brand, contains benzoyl peroxide (BPO). 

first reported benzene contamination in several BPO-containing acne products

 urging the US Food and Drug Administration (FDA) to take action.

The agency has not yet commented on whether additional recalls will follow.

L’Oréal stated that testing found trace levels of benzene in one lot of Effaclar Duo, leading the company to work closely with the FDA to proactively recall the product. 

The company also announced that an improved formulation, which has been in development since 2024, will soon be available.

 for exclusive insights from Christopher Bunick, MD, PhD.

Over the past year, multiple subsequent studies have investigated benzene contamination in BPO products. 

 confirmed widespread benzene contamination in 111 BPO products from major US retailers.

 that benzene levels increased with high-temperature processing but could be mitigated with antioxidants like BHT, highlighting the role of formulation and storage in contamination.

 While the chemical link between BPO and benzene is well established, the long-term health risks remain uncertain.

 analyzed BPO and its potential link to malignancies, finding a strong signal of increased cancer-related adverse event (AE) reports among BPO users. Using data from the FDA’s Adverse Event Reporting System, researchers identified 452 AE cases from 2019 to Q1 of 2024, with 23 (5.09%) classified as neoplasms, including skin and breast cancer. The study noted that reports of neoplasms increased significantly in the last 2 years.

Statistical analysis showed high reporting odds ratios for malignant neoplasms, skin cancer, and breast cancer, particularly in Proactiv products. While the study does not establish causality, it highlights concerns over benzene contamination in BPO products, aligning with prior research on the topic. 

 Editor in Chief Christopher Bunick, MD, PhD, emphasize the need for further studies to assess the long-term safety of BPO, particularly regarding its formulation, storage, and potential to generate benzene.

“The chemical formation of benzene from benzoyl peroxide is well established. Recent research has demonstrated many benzoyl peroxide products have benzene concentrations exceeding the emergency or conditional FDA limit of 2 ppm benzene," said Bunick in 

. "While these products are not in line with FDA regulatory policy, the health implications of benzene exposure from BPO products on consumers and patients is less understood. This new research in JID does not establish causality or potential for risk, but does identify a malignancy signal in the FDA’s own adverse event reporting database that warrants further studies into BPO.”

Edney A. L’Oreal recalls acne treatment on cancer-linked chemical. Bloomberg Law. March 10, 2025. Accessed March 10, 2025. 

https://news.bloomberglaw.com/health-law-and-business/loreal-recalls-acne-treatment-in-us-on-cancer-linked-benzene

Valisure citizen petition on benzene in benzoyl peroxide drug products. Valisure. March 5, 2024. Accessed March 10, 2025. 

https://assets-global.website-files.com/6215052733f8bb8fea016220/65e8560962ed23f744902a7b_Valisure%20Citizen%20Petition%20on%20Benzene%20in%20Benzoyl%20Peroxide%20Drug%20Products.pdf

Kucera K, Zenzola N, Hudspeth A, et al. Evaluation of benzene presence and formation in benzoyl peroxide drug products. 

Barbieri JS, Rubin CB, Pham JP, Wong M. The role of formulation in benzene formation in benzoyl peroxide products. 

Zhou S, Yan S, Ming S. A comprehensive study on adverse reactions of benzoyl peroxide (BPO) in dermatological aesthetics utilizing the FAERS database. 

The recall includes L'Oréal's Effaclar Duo product. Stay tuned for more updates throughout the day.

L'Oréal Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns

American Academy of Dermatology Annual Meeting in Orlando, Florida

, a poster from AbbVie showed that patients with psoriasis who are new to biologic therapy may have a reduced risk of psoriatic arthritis after reaching treatment goals established by the National Psoriasis Foundation.

 The real-world study was conducted using data from the CorEvitas Psoriasis Registry.

Nearly 40% of patients with psoriasis also develop psoriatic arthritis. Additionally, it has been proven that a greater disease severity of psoriasis is linked to a higher risk of psoriatic arthritis. The National Psoriasis Foundation (NPF) has outlined several acceptable and target treatment goals for patients. A Body Surface Area of ≤1 is the target response. Other acceptable measures include a Body Surface Area of ≤3% or ≥75% improvement from baseline. The study observed the incidence of psoriatic arthritis based on the achievement of these goals with biologic-naïve patients being treated for psoriasis.

Participants with a baseline Body Surface Area of >3% beginning their first biologic therapy were included in the trial. All had no history of psoriatic arthritis and were identified through the CorEvitas Psoriasis Registry. Investigators evaluated success based on the NPF treatment goals 3 to 15 months after the biologics were initiated. Incident psoriatic arthritis according to the Psoriasis Epidemiology Screening Tool (PEST) or rheumatological/dermatological diagnosis was measured up to 5 years after assessing NPF treatment goals. Additionally, incidence rates per 100 person-years (PY) were calculated among all participants. The Kaplan-Meier approach was also used to estimate the probability of remaining PsA-free over 5 years with censoring for loss of follow-up. 

A total of 1,352 patients were included in the study. Over 40% of the participants were female. The mean age was 47.8 years while the mean Body Surface Area was 17.6%. Out of the 1,352 patients who were able to be analyzed based on the NPF conditions, the incidence rate of psoriatic arthritis was 7.12 cases/100 PY (95%CI: 6.23-8.14). Of these, 70.9% met the target goal (

Overall, the psoriatic arthritis incidence rate was lower (6.46/100 PY, 95%CI: 5.47-7.62) than those who did not meet the target (8.82/100 PY, 95%CI: 7.04-11.07). Patients achieving the NPF Target Goal within 3-15 months of starting their first biologic therapy for PsO were 27% less likely to develop PsA during the 5-year follow-up compared to those who did not meet the NPF Target Goal  (HR: 0.73, 95% CI: 0.55-0.96).

With these findings, it can be inferred that with the initial use of biologic therapy, those who achieved the psoriasis NPF target goal could have a reduced risk of developing psoriatic arthritis. 

1. Strober B, Patel M, Bialik B, et al. Incidence of Psoriatic Arthritis in Biologic-Naïve Psoriasis Patients Achieving National Psoriasis Foundation’s Treat to Target Goals: A Real-World Study With the CorEvitasPsoriasis Registry. Poster presented at the 2025 American Academy of Dermatology Annual Meeting. Orlando, Florida. March 7 to 11, 2025.

According to a poster from AAD, the National Psoriasis Foundation’s treatment goals were used as a benchmark to determine the risk of developing psoriatic arthritis after initiating biologics.

Amit Pandya, MD

Articles

Latest Updated Articles